Prevention of hepatorenal syndrome in patients with cirrhosis and ascites: A pilot randomized control trial between pentoxifylline and placebo

European Journal of Gastroenterology and Hepatology

Volumn 23, Issue 3, 2011, Pages 210-217

  Tyagi, Pankaj ^a   Sharma, Praveen ^a   Sharma, Barjesh Chander ^a   Puri, Amarender Singh ^a   Kumar, Ashish ^a   Sarin, Shiv Kumar ^a  

^a G B PANT HOSPITAL   (India)

Author keywords

ascites; cirrhosis; hepatorenal syndrome; pentoxifylline

Indexed keywords

CREATININE; PENTOXIFYLLINE; PLACEBO; PROTON PUMP INHIBITOR; SODIUM; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; ASCITES; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DYSPEPSIA; FEMALE; FOLLOW UP; HEPATORENAL SYNDROME; HOSPITAL ADMISSION; HUMAN; KIDNEY FUNCTION TEST; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MORTALITY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SODIUM BLOOD LEVEL;

ADULT; ASCITES; CREATININE; FEMALE; HEPATORENAL SYNDROME; HUMANS; KIDNEY FUNCTION TESTS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; PILOT PROJECTS; SODIUM; TUMOR NECROSIS FACTORS;

EID: 79951942093     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283435d76     Document Type: Article

References (34)

1. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of the hepato-renal syndrome in cirrhosis. Gut 2007; 56:1310-1318. (Pubitemid 47300435)
2. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepato-renal syndrome in cirrhosis. Hepatology 1996; 23:164-176. (Pubitemid 26012105)
3. Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105:229-236. (Pubitemid 23234041)
4. Watt K, Uhanova J, Minuk GY. Hepatorenal syndrome: diagnostic accuracy, clinical features, and outcome in a tertiary care center. Am J Gastroenterol 2002; 97:2046-2050.
5. Sharma P, Kumar A, Sharma BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol 2008; 103:1689-1697.
6. Duvoux C, Zanditenas D, Hezode C, Chauvat A, Monin JL, Roudot-Thoraval F, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002; 36:374-380. (Pubitemid 34810356)
7. Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003; 18:152-156. (Pubitemid 36349860)
8. Kiser TH, Fish DN, Obritsch MD, Jung R, MacLaren R, Parikh CR. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrol Dial Transplant 2005; 20:1813-1820. (Pubitemid 41222593)
9. Neri S, Pulvirenti D, Malaguarnera M, Cosimo BM, Bertino G, Ignaccolo L. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci 2008; 53:830-835. (Pubitemid 351317073)
10. Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134:1360-1368. (Pubitemid 351615358)
11. Martin-Llahi M, Pepin MN, Guevara M, Diaz F, Torre A, Monescillo A, et al. Terlipressin and albumin vs. albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008; 134:1352-1359. (Pubitemid 351626950)
12. Star RA. Treatment of acute renal failure. Kidney Int 1998; 54:1817-1831.
13. Tomlanovich S, Golbetz H, Perlroth M, Stinson E, Myers BD. Limitations of creatinine in quantifying the severity of cyclosporine-induced chronic nephropathy. Am J Kidney Dis 1986; 8:332-337. (Pubitemid 17235079)
14. Baboolal K, Jones GA, Janezic A, Griffiths DR, Jurewicz WA. Molecular and structural consequences of early renal allograft injury. Kidney Int 2002; 61:686-696. (Pubitemid 34102612)
15. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341:403-409. (Pubitemid 29362513)
16. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O, et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119:1637-1648. (Pubitemid 32198689)
17. Fernández J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133:818-824. (Pubitemid 47374144)
18. Aparicio JR, Such J, Pascual S, Arroyo A, Plazas J, Girona E, et al. Development of quinolone-resistant strains of Escherichia coli in stools of patients with cirrhosis undergoing norfloxacin prophylaxis: clinical consequences. J Hepatol 1999; 31:277-283. (Pubitemid 29349754)
19. Byl B, Roucloux I, Crusiaux A, Dupont E, Deviere J. Tumor necrosis factor alpha and interleukin-6 plasma levels in infected cirrhotic patients. Gastroenterology 1993; 104:1492-1497. (Pubitemid 23235425)
20. Tazi KA, Quioc JJ, Saada V, Bezeaud A, Lebrec D, Moreau R. Upregulation of TNF-alpha production signalling pathways in monocytes from patients with advanced cirrhosis: possible role of Akt and IRAK-M. J Hepatol 2006; 45:280-289. (Pubitemid 44026567)
21. McClain C, Cohen D. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology 1989; 9:349-351. (Pubitemid 19074964)
22. Satapathy SK, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007; 22:634-638. (Pubitemid 46608380)
23. Yalniz M, Bahcecioglu IH, Kuzu N, Celebi S, Ataseven H, Ustundag B. Amelioration of steatohepatitis with pentoxifylline in a novel nonalcholic steatohepatitis model induced by high-fat diet. Dig Dis Sci 2007; 52:2380-2386. (Pubitemid 47246482)
24. Sztrymf B, Rabiller A, Nunes H, Savale L, Lebrec D, Le Pape A, et al. Prevention of hepatopulmonary syndrome and hyperdynamic state by pentoxifylline in cirrhotic rats. Eur Respir J 2004; 23:752-758. (Pubitemid 38618148)
25. Lebrec D, Thabut D, Oberti F, Perarnau JM, Condat B, Barraud H, et al. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology 2010; 138:1755-1762.
26. Runyon BA; Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Management of adult patients with ascites due to cirrhosis. Hepatology 2004; 39:841-856.
27. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
28. Terg R, Fassio E, Guevara M, Cartier M, Longo C, Lucero R, et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study. J Hepatol 2008; 48:774-779.
29. Dupeyron C, Mangeney N, Sedrati L, Campillo B, Fouet P, Leluan G, et al. Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. Antimicrob Agents Chemother 1994; 38:340-344. (Pubitemid 24054258)
30. Ortiz J, Vila MC, Soriano G, Minana J, Gana J, Mirelis B, et al. Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients. Hepatology 1999; 29:1064-1069. (Pubitemid 29168737)
31. Novella M, Solà R, Soriano G, Andreu M, Gana J, Ortiz J, et al. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Hepatology 1997; 25:532-536.
32. Strutz F, Heeg M, Kochsiek T, Regenstein F, Rossaro L, Appenrodt B. Effects of pentoxifylline, pentifylline and gamma-interferon on proliferation, differentiation, and matrix synthesis of human renal fibroblasts. Nephrol Dial Transplant 2000; 15:1535-1546.
33. Hewitson TD, Martic M, Kelynack KJ, Pedagogos E, Becker GK. Pentoxifylline reduces in vitro renal myofibroblast proliferation and collagen secretion. Am J Nephrol 2000; 20:82-88. (Pubitemid 30047877)
34. Ernst E. Pentoxifylline for intermittent claudication: a critical review. Angiology 1994; 45:339-345. (Pubitemid 24142661)